Arcutis Biotherapeutics (ARQT) Research & Development (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Research & Development of $30.6 million for Q1 2026, up 74.58% year-over-year from $17.5 million in Q1 2025, and up 49.76% quarter-over-quarter from $20.5 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Research & Development (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $30.6 million for Q1 2026.
- In Q1 2026, Research & Development rose 74.58% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at $90.1 million (up 27.27% YoY), while the FY2025 annual figure was $77.1 million, up 0.83% from the prior year.
- Research & Development for Q1 2026 stood at $30.6 million, up from $20.5 million in the prior quarter.
- The five-year high for Research & Development was $40.6 million in Q1 2022, with the low at $14.5 million in Q4 2024.
- The 5-year median for Research & Development is $23.8 million (2023), against an average of $25.7 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development jumped 87.8% in 2022, then plunged 39.1% in 2024.
- Arcutis Biotherapeutics' Research & Development stood at $33.9 million in 2022, then fell by 29.82% to $23.8 million in 2023, then slumped by 39.1% to $14.5 million in 2024, then surged by 41.24% to $20.5 million in 2025, then jumped by 49.76% to $30.6 million in 2026.
- Business Quant data shows ARQT's Research & Development at $30.6 million in Q1 2026, $20.5 million in Q4 2025, and $19.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 20.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.36 Mn |
| Mar 31, 2026 | 30.63 Mn |
| Dec 31, 2025 | 20.45 Mn |
| Sep 30, 2025 | 19.60 Mn |
| Jun 30, 2025 | 19.45 Mn |
| Mar 31, 2025 | 17.54 Mn |
| Dec 31, 2024 | 14.48 Mn |
| Sep 30, 2024 | 19.50 Mn |
| Jun 30, 2024 | 19.30 Mn |
| Mar 31, 2024 | 23.14 Mn |
| Dec 31, 2023 | 23.78 Mn |
| Sep 30, 2023 | 26.24 Mn |
| Jun 30, 2023 | 25.22 Mn |
| Mar 31, 2023 | 35.35 Mn |
| Dec 31, 2022 | 33.88 Mn |
| Sep 30, 2022 | 29.60 Mn |
| Jun 30, 2022 | 38.21 Mn |
| Mar 31, 2022 | 40.62 Mn |
| Dec 31, 2021 | 52.56 Mn |
| Sep 30, 2021 | 40.60 Mn |